Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00895466

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.

Sponsor: Pepscan Therapeutics

Conditions Prostate Cancer

Interventions PEP-223/CoVaccine HT

Updated 5 times since 2017 Last updated: May 7, 2009 Started: Oct 31, 2008 Primary completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00895466, this PHASE1/PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by Pepscan Therapeutics, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pepscan Therapeutics
TFS Trial Form Support

Data source: Pepscan Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands
• Nijmegen, Netherlands